Luigi Quintieri
Department of Pharmaceutical and Pharmacological Sciences, University of Padova e-mail: luigi.quintieri@unipd.it |
Short CV
Education
July 1994: Degree in Pharmacy with honors, Faculty of Pharmacy, University of Padova
December 1994: qualification for the profession of Pharmacist, University of Padova
February 2002 : PhD degree in Oncology, Faculty of Medicine and Surgery, University of Padova
Scientific activity
1994 – 1995: visiting graduate atInstituteofOncology, Chair of Immunology, UniversityofPadova
1996 – 1998: research fellow of the “Associazione Italiana perla Ricercasul Cancro (AIRC)” at Department of Oncology and Surgical Sciences, Section of Oncology, University of Padova
1999 – 2001: Ph.D. student in Oncology at Department of Oncology and Surgical Sciences, Section of Oncology, University of Padova
December 2001 - May 2002: consultant of the “Centro Oncologico Regionale - Azienda Ospedaliera di Padova”, Padova
June 2002 - May 2004: postdoctorate fellow in Pharmaceutical Sciences at Department of Pharmacology and Anesthesiology, University of Padova
July 2004 – June 2005: Research fellow of the “Azienda Unità Locale Socio Sanitaria n.16” of Padova
March 2006 – present: Assistant Professor, University of Padova
Professional memberships
Member of the Società Italiana di Farmacologia (SIF)
Member of the Editorial Board of Anti-cancer Agents in Medicinal Chemistry (ACAMC)
Teaching
Office hours
Reception days and times are flexible; to book an appointment, please contact me at: luigi.quintieri@unipd.it
Availability for Thesis Projects
Pharmacology of novel inhibitors of glutathione transferase P1-1 for cancer therapy; in vitro characterization of the metabolic fate of xenobiotics; impact of antiangiogenesis on metabolic features of tumor cells (in collaboration with Dr. S. Indraccolo).
Research
Scientific Activities
My areas of research interest include phase I and phase II metabolism of drugs, the pharmacological characterization of novel inhibitors of glutathione transferase P1-1 for cancer therapy, and the impact of antiangiogenic therapy on the metabolic features of tumor cells and tumor response to chemotherapy. The research programs require an interdisciplinary approach, and are carried out in cooperation with other members of Dept. of Pharmaceutical and Pharmacological Sciences, as well as with other national and international researchers.
Technical expertise
- preparation of subcellular fractions from whole tissue or cell culture homogenates
- identification/quantitation of drugs and their metabolites in different matrices by high-performance liquid chromatography coupled to diode array or fluorescence detection
- HPLC-based evaluation ofcytochrome P450, UDP-glucuronosyltransferase, and glutathione transferase enzyme activities
- HPLC-based quantitation of oxidative stress markers (glutathione, malonyldialdehyde and hydrogen peroxide) in biological matrices
Publications
- De Luca A, Rotili D, Carpanese D, Lenoci A, Calderan L, Scimeca M, Mai A,Bonanno E, Rosato A, Geroni C, Quintieri L, and Caccuri AM. A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent andselective antitumor activity against human melanoma xenografts. Oncotarget. 2015;6:4126-43.
- Quintieri L, Selmy M, and Indraccolo S. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. Biochem Pharmacol. 2014;89:162-70.
- Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A,Palatini P, Floreani M. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet. 2010;25:466-76.
- Ruzza P, Rosato A, Nassi A, Rondina M, Zorzin M, Rossi CR, Floreani M, and Quintieri L. Synthesis and preliminary in vitro biological evaluation of 4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one, a 4-mercaptophenol derivative designed as a novel bifunctional antimelanoma agent. J Med Chem 2009; 52:4973-6.2008;75:1426-37
- Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, Zanovello P, and Floreani M. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res. 2005;11:1608-17
Research projects
2013-2016: Investigator Grant 2013, Associazione Italiana perla Ricercasul Cancro (AIRC), 315.000 Euro - Participant
Metabolic effects of anti-angiogenic therapy in cancer and their therapeutic implications (IG14295)
February 2013- February 2016: PRIN GRANT 2010-2011, Italian Ministry of Scientific Research (MIUR), 74.000 Euro - Participant
Progettazione e sintesi di sonde molecolari per lo studio del ruolo della microglia in patologie correlate alla neuroinfiammazione (20103W4779_002)
February 2012-july 2015: Progetti di Ricerca di Ateneo 2011, Università di Padova, 41.000 Euro - PI
Progettazione, sintesi e valutazione biologica di analoghi della sulfasalazina quali chemiosensibilizzatori per la terapia del melanoma (CPDA118910/11)
March 2007- August 2009: Progetti di Ricerca di Ateneo – 2006, Università di Padova, 40.000 Euro - Participant
Progettazione, sintesi e valutazione biologica di coniugati peptidici del paclitaxel per la terapia del melanoma (CPDA064182)
2001 – 2002: “Agenzia2000 – giovani ricercatori”grant, National Research Council of Italy (CNR), 20.000.000 Lire – PI
Biotrasformazione epatica in vitro della metossimorfolinil doxorubicina (MMDX): separazione e identificazione di metaboliti prodotti attraverso l’intervento di citocromo P450 3A (CNRG00C1F7)
2010-present: ex 60% research funds, Italian Ministry of Scientific Research (MIUR) - PI
Pharmacological characterization of novel GSTP1-1 inhibitors
